Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma

Clinical Cancer Research

Volumn 14, Issue 10, 2008, Pages 3156-3167

  Kline, Justin ^a   Brown, Ian E ^b   Zha, Yuan Yuan ^b   Blank, Christian ^b   Strickler, John ^b   Wouters, Harald ^b   Zhang, Long ^a   Gajewski, Thomas F ^a,b  

^a Department of Medicine ^*

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CD25+ T LYMPHOCYTE; CLONAL ANERGY; CONTROLLED STUDY; HOMEOSTASIS; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR REJECTION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METHODOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CLONAL ANERGY; FLOW CYTOMETRY; HOMEOSTASIS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, REGULATORY;

EID: 49649121241     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4696     Document Type: Article

References (37)

1. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999:10:281 -7.
2. Harlin H, KunaTV, Peterson AC, et al. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 2006:55:1185-97.
3. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006:213:131 - 45.
4. Koneru M, Schaer D, Monu N, et al. Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function. J Immunol 2005; 174: 1830-40.
5. Mizoguchi H. O'Shea J J, Longo DL, et al. Alterations in signal transduction molecules in T. lymphocytes from tumor-bearing mice. Science 1992;258:1795-8.
6. Brown IE, Blank C, Kline J, et al. Homeostatic proliferation as an isolated variable reverses CD8+ T-cell anergy and promotes tumor rejection. J Immunol 2006;177:4521-9
7. Alexander JP, Kudoh S, Melsop KA, et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 1993; 53:1380-7.
8. Meng Y, Harlin H, O'Keefe JP, et al. Induction of cytotoxic granules in human memory CD8+ Tcell subsets requires cell cycle progression. J Immunol 2006;177: 1981-7
9. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005:437:141-6.
10. Townsend SE, Allison JP, Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993:259:368 - 70.
11. Shimizu J, Yamazaki S, Takahashi T, et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135-42.
12. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61.
13. Fontenot JD. Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005;6:331-7.
14. Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cells and tumor immunity. Cancer Immunol Immunother 2005:54:1153-61.
15. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006:6: 295 - 307.
16. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory Tcells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001:194: 834-42.
17. Ko K, Yamazaki S, Nakamura K, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+regulatory T cells J Exp Med 2005;202:885-91.
18. Turk MJ, Guevara-Patino JA, Rizzuto GA, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004:200:771 -82.
19. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999:163:5211 -8.
20. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurnng T regulatory cells. J Immunol 2005:174 2591 -601.
21. Gattinoni L, Powell DJ, Rosenberg SA. et al Adoptive immunotherapy for cancer: building on success Nat Rev Immunol 2006:6:383-93.
22. Fontenot JD. Rasmussen JP, Williams LM. et al Regulatory T cell lineage specification by the fork-head transcription factor foxp3. Immunity 2005:22 329-41.
23. Blank C, Brown I, Peterson AC, et al PD-L1 B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004;64:1140-5.
24. Kranz DM, Tonegawa S, Eisen HN Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1984:81 7922-6
25. Spiotto MT. Yu P. Rowley DA. et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002:17:737-47
26. Sanderson K, Scotland R. Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma J Clin Oncol 2005:23:741 -50.
27. Onizuka S. Tawara I, Shimizu J. et al Tumor reaction by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res 1999. 59:3128-33.
28. Boussiotis VA, Barber DL, Nakarai T, et al Prevention of T cell anergy by signaling through the γc chain of the IL-2 receptor. Science1994;266: 1039-42.
29. Teague RM, Sather BD, Sacks JA, et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 2006;12:335-41.
30. Zha Y. Marks R, Ho AW, et al. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-α. Nat Immunol 2006;7:1166-73.
31. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74.
32. Frey AB. Myeloid suppressor cells regulate the adaptive immune response to cancer. J Clin Invest 2006;116:2587-90.
33. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory Tcells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003;198:1875-86.
34. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33.
35. Attia P, Maker AV, Haworth LR, et al. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immun-other 2005;28:582-92.
36. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
37. Powell DJ, de Vries CR, Allen T, et al. Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. J Immunother 2007;30:438-47.